

ACIP Provisional Recommendations for Use of 13-valent Pneumococcal Conjugate Vaccine in Adults with Immunocompromising Conditions

Date of ACIP vote: June 20, 2012

Date of posting of provisional recommendations: September 18, 2012

Estimated date of policy note in MMWR: October 12, 2012

On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Pfizer) for adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants (Table 1). PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax, Merck & Co. Inc.), the vaccine recommended for these groups of adults since 1997.

- 1) Recommendation for the use of PCV13 among pneumococcal vaccine naïve individuals:
 - Adults 19 years of age or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first followed by a dose of PPSV23 at least 8 weeks later (Table 1).
 - Subsequent doses of PPSV23 should follow current PPSV23 recommendations for these adults. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19–64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. Persons with CSF leaks or cochlear implants should receive no additional doses of PPSV23 until age 65 years.
 - Additionally, those who received 1 or 2 doses of PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years or later if at least 5 years have elapsed since their previous PPSV23 dose.

- 2) Recommendations for the use of PCV13 among adults who have previously been vaccinated with PPSV23:
 - Adults 19 years of age or older with the aforementioned conditions who have previously received one or more doses of PPSV23 should be given a dose of PCV13 one or more years after the last PPSV23 dose was received. For those who require additional doses of PPSV23 (see Table 1), the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23.

Additional information regarding the use of PPSV23 and PCV13 can be found in the following documents:

1. Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23). Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm>

2. Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine.
Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm>

3. Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older.
Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a3.htm>

Table 1. Medical conditions or other indications for administration of 13-valent pneumococcal conjugate vaccine (PCV13), as well as indications for 23-valent pneumococcal polysaccharide vaccine (PPSV23) administration and revaccination for adults aged 19-64 years.

Risk Group	Underlying Medical Condition	PCV13	PPSV23	
		Recommended	Recommended	Revaccination at 5 years
Immunocompetent persons	Chronic heart disease		✓	
	Chronic lung disease		✓	
	Diabetes mellitus		✓	
	CSF leaks	✓	✓	
	Cochlear implants	✓	✓	
	Alcoholism		✓	
	Chronic liver disease		✓	
	Cigarette smoking		✓	
Persons with functional or anatomic asplenia	Sickle cell disease/other hemaglobinopathies	✓	✓	✓
	Congenital or acquired asplenia	✓	✓	✓
Immunocompromised persons	Congenital or acquired immunodeficiencies	✓	✓	✓
	HIV infection	✓	✓	✓
	Chronic renal failure	✓	✓	✓
	Nephrotic syndrome	✓	✓	✓
	Leukemia	✓	✓	✓
	Lymphoma	✓	✓	✓
	Hodgkin disease	✓	✓	✓
	Generalized malignancy	✓	✓	✓
	Iatrogenic immunosuppression	✓	✓	✓
	Solid organ transplant	✓	✓	✓
Multiple myeloma	✓	✓	✓	